 |
94 Diseases |  |
58 Trials |
|
58 Trials |  |
2914 News |  |
| «12...27282930313233343536373839» |
- | Mifeprex (mifepristone) / Danco Laboratories
Trial initiation date: Triple M: Comparing Two Medical Treatments for Early Pregnancy Failure. (clinicaltrials.gov) - Apr 19, 2018
P4, N=460, Not yet recruiting, Sponsor: Radboud University
Initiation date: Feb 2018 --> Jun 2018
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment open: IMEGYN: Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination (clinicaltrials.gov) - Apr 19, 2018
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Initiation date: Feb 2018 --> Jun 2018 Not yet recruiting --> Recruiting
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion date, Trial initiation date, Trial primary completion date: Medication Abortion Via Pharmacy Dispensing (clinicaltrials.gov) - Apr 18, 2018
P4, N=250, Not yet recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting Trial completion date: Dec 2019 --> Jul 2019 | Initiation date: Nov 2017 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Jul 2019
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion date, Trial primary completion date, BRCA Biomarker, IO biomarker: BRCA1/2 and Effect of Mifepristone on the Breast (clinicaltrials.gov) - Mar 6, 2018
P2, N=45, Recruiting, Sponsor: Karolinska Institutet
Trial completion date: Dec 2019 --> Jul 2019 | Initiation date: Nov 2017 --> Jun 2018 | Trial primary completion date: Dec 2019 --> Jul 2019 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
Enrollment open, Trial initiation date, Metastases: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer (clinicaltrials.gov) - Feb 28, 2018
P2, N=74, Recruiting, Sponsor: University of Chicago
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018
- | Mifeprex (mifepristone) / Danco Laboratories
New trial: Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion. (clinicaltrials.gov) - Feb 22, 2018
P=N/A, N=250, Not yet recruiting, Sponsor: HaEmek Medical Center, Israel
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion, Trial completion date: Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients (clinicaltrials.gov) - Feb 19, 2018
P2/3, N=59, Completed, Sponsor: New York State Psychiatric Institute
Not yet recruiting --> Recruiting | Initiation date: Mar 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Feb 2018
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, Metastases: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (clinicaltrials.gov) - Jan 11, 2018
P1/2, N=108, Recruiting, Sponsor: University of Chicago
Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> Jul 2018
- | Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
Trial initiation date, Metastases: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer (clinicaltrials.gov) - Jan 11, 2018
P2, N=74, Not yet recruiting, Sponsor: University of Chicago
Trial primary completion date: Dec 2017 --> Jul 2018 Initiation date: Dec 2017 --> Mar 2018
- | Mifeprex (mifepristone) / Danco Laboratories
Trial withdrawal: Second Trimester Labor Induction (clinicaltrials.gov) - Dec 8, 2017
P1, N=0, Withdrawn, Sponsor: Johns Hopkins University
Initiation date: Dec 2017 --> Mar 2018 Terminated --> Withdrawn
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 7, 2017
P1, N=31, Active, not recruiting, Sponsor: University of Chicago
Terminated --> Withdrawn Trial primary completion date: Nov 2017 --> Jun 2018
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion, Enrollment change: Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults (clinicaltrials.gov) - Dec 2, 2017
P1/2, N=63, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Nov 2017 --> Jun 2018 Recruiting --> Completed | N=80 --> 63
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: Outpatient Service for Mid-trimester Termination of Pregnancy (clinicaltrials.gov) - Nov 17, 2017
P4, N=230, Not yet recruiting, Sponsor: Gynuity Health Projects
- | Mifeprex (mifepristone) / Danco Laboratories
Journal: Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors. (Pubmed Central) - Nov 8, 2017
Lastly, doses of proteasome inhibitors that are inadequate to block the activity of the proteasomes, caused cell death when combined with mifepristone; this phenotype was accompanied by accumulation of poly-ubiquitinated proteins denoting proteasome inhibition. The stimulation by mifepristone of ER stress and autophagic flux offers a therapeutic opportunity for utilizing this compound to sensitize ovarian cancer cells to proteasome or lysosome inhibitors.
- | Mifeprex (mifepristone) / Danco Laboratories
Trial initiation date, Trial primary completion date: IMEGYN: Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination (clinicaltrials.gov) - Nov 1, 2017
P=N/A, N=120, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
The stimulation by mifepristone of ER stress and autophagic flux offers a therapeutic opportunity for utilizing this compound to sensitize ovarian cancer cells to proteasome or lysosome inhibitors. Initiation date: Sep 2017 --> Jan 2018 | Trial primary completion date: Jan 2019 --> May 2019
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: Medication Abortion Via Pharmacy Dispensing (clinicaltrials.gov) - Oct 25, 2017
P4, N=250, Not yet recruiting, Sponsor: University of California, San Francisco
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment closed, Trial primary completion date: Medication Enhanced Rapid Therapy (clinicaltrials.gov) - Oct 11, 2017
P1, N=90, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Sep 2017 --> Jan 2018 | Trial primary completion date: Jan 2019 --> May 2019 Trial primary completion date: Aug 2017 --> Aug 2018 | Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
Trial initiation date, Metastases: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer (clinicaltrials.gov) - Oct 10, 2017
P2, N=74, Not yet recruiting, Sponsor: University of Chicago
Trial primary completion date: Aug 2017 --> Aug 2018 | Recruiting --> Active, not recruiting Initiation date: Sep 2017 --> Dec 2017
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment open: MifeMiso: Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage (clinicaltrials.gov) - Oct 6, 2017
P3, N=710, Recruiting, Sponsor: University of Birmingham
Initiation date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, Metastases: Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Sep 12, 2017
P1, N=32, Active, not recruiting, Sponsor: University of Chicago
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Jun 2018
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion: 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E (clinicaltrials.gov) - Sep 7, 2017
P4, N=72, Completed, Sponsor: Virginia Commonwealth University
Trial primary completion date: Jun 2017 --> Jun 2018 Recruiting --> Completed
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion: Acceptability and Feasibility of Medical Abortion in Singapore (clinicaltrials.gov) - Aug 31, 2017
P3, N=125, Completed, Sponsor: Gynuity Health Projects
Recruiting --> Completed Active, not recruiting --> Completed
- | Mifeprex (mifepristone) / Danco Laboratories
New P3 trial: Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso (clinicaltrials.gov) - Aug 31, 2017
P3, N=100, Recruiting, Sponsor: Gynuity Health Projects
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion, Enrollment change, Trial primary completion date: STOMP-CSC: Short-Term Oral Mifepristone for Central Serous Chorioretinopathy (clinicaltrials.gov) - Jul 26, 2017
P2, N=16, Completed, Sponsor: Roger Goldberg, M.D., MBA
Active, not recruiting --> Completed Recruiting --> Completed | N=30 --> 16 | Trial primary completion date: Dec 2016 --> Apr 2017
- | Keytruda (pembrolizumab) / Merck (MSD), Mifeprex (mifepristone) / Danco Laboratories
New P2 trial, Metastases: Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer (clinicaltrials.gov) - Jul 20, 2017
P2, N=74, Not yet recruiting, Sponsor: University of Chicago
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment closed, Enrollment change: Acceptability and Feasibility of Medical Abortion in Singapore (clinicaltrials.gov) - Jul 14, 2017
P3, N=125, Active, not recruiting, Sponsor: Gynuity Health Projects
Recruiting --> Completed | N=30 --> 16 | Trial primary completion date: Dec 2016 --> Apr 2017 Recruiting --> Active, not recruiting | N=220 --> 125
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: Triple M: Comparing Two Medical Treatments for Early Pregnancy Failure. (clinicaltrials.gov) - Jul 11, 2017
P4, N=460, Not yet recruiting, Sponsor: Canisius-Wilhelmina Hospital
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy (clinicaltrials.gov) - Jul 5, 2017
P4, N=2200, Recruiting, Sponsor: China Resources Zizhu Pharmaceutical Co., Ltd.
- | Mifeprex (mifepristone) / Danco Laboratories
Trial completion: Clinical Trial of Mifepristone for Bipolar Depression (clinicaltrials.gov) - Jun 30, 2017
P2, N=110, Completed, Sponsor: National Institute of Mental Health (NIMH)
Recruiting --> Active, not recruiting | N=220 --> 125 No longer recruiting --> Completed
- | Mifeprex (mifepristone) / Danco Laboratories
New trial: IMEGYN: Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination (clinicaltrials.gov) - Jun 20, 2017
P=N/A, N=120, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, IO biomarker: MIPRA: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B. (clinicaltrials.gov) - Jun 12, 2017
P=N/A, N=20, Recruiting, Sponsor: Hospital Provincial Magdalena V. de Mart
No longer recruiting --> Completed Trial primary completion date: Sep 2017 --> Jul 2018
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment closed, Enrollment change: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 12, 2017
P1, N=31, Active, not recruiting, Sponsor: University of Chicago
Trial primary completion date: Sep 2017 --> Jul 2018 Recruiting --> Active, not recruiting | N=22 --> 31
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment closed, Trial primary completion date, HEOR: Comparative Effectiveness of Pregnancy Failure Management Regimens (clinicaltrials.gov) - May 5, 2017
P3, N=300, Active, not recruiting, Sponsor: University of Pennsylvania
Recruiting --> Active, not recruiting | N=22 --> 31 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> May 2017
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E (clinicaltrials.gov) - Apr 27, 2017
P4, N=72, Recruiting, Sponsor: Virginia Commonwealth University
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Mifeprex (mifepristone) / Danco Laboratories
Enrollment open, Metastases: Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer (clinicaltrials.gov) - Mar 15, 2017
P1/2, N=108, Recruiting, Sponsor: University of Chicago
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> May 2017 Active, not recruiting --> Recruiting
- | Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, BRCA Biomarker, IO biomarker: BRCA1/2 and Effect of Mifepristone on the Breast (clinicaltrials.gov) - Mar 3, 2017
P2, N=45, Recruiting, Sponsor: Karolinska Institutet
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment change: Cervical Rippening With Antiprogesterone in Midtrimester Abortions (clinicaltrials.gov) - Mar 1, 2017
P4, N=145, Completed, Sponsor: Hadassah Medical Organization
Trial primary completion date: Dec 2016 --> Dec 2017 N=50 --> 145
- | Mifeprex (mifepristone) / Danco Laboratories
New P3 trial: MifeMiso: Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage (clinicaltrials.gov) - Feb 27, 2017
P3, N=710, Not yet recruiting, Sponsor: University of Birmingham
- Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Mifepristone for the Prevention of Relapses of Alcohol Drinking (clinicaltrials.gov) - Feb 7, 2017
P1/2, N=20, Recruiting, Sponsor: Brown University
N=50 --> 145 Trial primary completion date: Dec 2016 --> Dec 2017
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion (clinicaltrials.gov) - Feb 6, 2017
P4, N=200, Recruiting, Sponsor: Rambam Health Care Campus
- Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) (clinicaltrials.gov) - Jan 31, 2017
P2, N=24, Recruiting, Sponsor: Indiana University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Mifeprex (mifepristone) / Danco Laboratories
Trial completion, Enrollment change: A Controlled Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness (clinicaltrials.gov) - Jan 30, 2017
P4, N=65, Completed, Sponsor: Bronx Veterans Medical Research Foundation, Inc
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=40 --> 65
- || Mifeprex (mifepristone) / Danco Laboratories
New P3 trial: SWOG-9005: S9005 Mifepristone in Meningioma (clinicaltrials.gov) - Jan 10, 2017
P3, N=193, Completed, Sponsor: Southwest Oncology Group
- Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date, Metastases: Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Dec 29, 2016
P1, N=32, Active, not recruiting, Sponsor: University of Chicago
Recruiting --> Completed | N=40 --> 65 Trial primary completion date: Nov 2016 --> Jun 2017
- Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 29, 2016
P1, N=22, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Nov 2016 --> Jun 2017 Trial primary completion date: Nov 2016 --> Nov 2017
- || Mifeprex (mifepristone) / Danco Laboratories
New P3 trial: Acceptability and Feasibility of Medical Abortion in Singapore (clinicaltrials.gov) - Dec 9, 2016
P3, N=220, Recruiting, Sponsor: Gynuity Health Projects
- Mifeprex (mifepristone) / Danco Laboratories
Trial primary completion date: Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults (clinicaltrials.gov) - Dec 7, 2016
P1/2, N=80, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Trial primary completion date: Nov 2016 --> Nov 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- | Mifeprex (mifepristone) / Danco Laboratories
New P4 trial: Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine (clinicaltrials.gov) - Dec 2, 2016
P4, N=100, Recruiting, Sponsor: Gynuity Health Projects
- | Mifeprex (mifepristone) / Danco Laboratories
Enrollment change, Trial primary completion date: Investigation of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients (clinicaltrials.gov) - Oct 26, 2016
P2/3, N=59, Active, not recruiting, Sponsor: New York State Psychiatric Institute
Trial primary completion date: Dec 2016 --> Dec 2017 N=80 --> 59 | Trial primary completion date: Dec 2015 --> Sep 2016
- Mifeprex (mifepristone) / Danco Laboratories
Enrollment open, Trial primary completion date: MIFD: Mifepristone Induction for Fetal Demise (clinicaltrials.gov) - Oct 17, 2016
P4, N=74, Recruiting, Sponsor: Montefiore Medical Center
N=80 --> 59 | Trial primary completion date: Dec 2015 --> Sep 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2017 --> Sep 2018